CRMD - NASDAQ
CorMedix Inc.
$8.23
+0.73%CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
At a Glance
Live SnapshotCorMedix Inc. Management Team
Mr. Joseph Todisco MBA
Chief Executive Officer & Director
Compensation
$1,151,455
Ms. Kaufman Beth Zelnick Esq.
EVice President, Chief Legal, Compliance Officer & Corporate Secretary
Ms. Erin Mistry
Executive Vice President & Chief Commercial Officer
Compensation
$561,571
Dr. Matthew T. David M.D.
Executive Vice President & Chief Financial Officer
Compensation
$634,855
Ms. Elizabeth Masson-Hurlburt B.A.
Executive Vice President and Chief Clinical Strategy & Operations Officer
Compensation
$682,195
Donna Ucci
Senior Vice President & Head of Global Quality
Dr. Tushar Mukherjee
Senior Vice President & Head of Technical Operations
CorMedix Inc. Insider Positioning
During the last 12 months, insiders have purchased $386K and sold $2.64M worth of CRMD shares, resulting in $2.26M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
134.0K
1.57M
-1.6M
-$1.57M
6-9 Months
38.3K
386.43K
103.0K
1.07M
-684K
-$684K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Kaplan Myron
Director
$276K
Duncan Gregory Scott
Director
$111K
Top Sellers
Dillione Janet
Director
$1.55M
Lefkowitz Steven W
Director
$475K
Todisco Joseph
Director, Officer: Chief Executive Officer
$360K
Dunton Alan W
Director
$260K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $2.26M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Insider Participation
4 insider sellers vs. 2 buyers. More insiders selling than buying suggests cautious or negative sentiment.
SEC Filings
CRMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 23, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | October 24, 2025 | November 10, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | October 08, 2024 | November 21, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | September 13, 2023 | October 26, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | August 30, 2022 | October 13, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | October 29, 2021 | December 09, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | November 04, 2020 | December 16, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | October 17, 2019 | November 26, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | November 01, 2018 | December 11, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.